These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15830342)

  • 1. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells.
    Kim R; Tanabe K; Emi M; Uchida Y; Toge T
    Cancer; 2005 May; 103(10):2199-207. PubMed ID: 15830342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
    Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma.
    Kim R; Tanabe K; Uchida Y; Emi M; Toge T
    Int J Mol Med; 2003 Jun; 11(6):799-804. PubMed ID: 12736725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels.
    Zhang GJ; Kimijima I; Onda M; Kanno M; Sato H; Watanabe T; Tsuchiya A; Abe R; Takenoshita S
    Clin Cancer Res; 1999 Oct; 5(10):2971-7. PubMed ID: 10537367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma.
    Kim R; Emi M; Tanabe K; Toge T
    Cancer; 2004 Nov; 101(10):2177-86. PubMed ID: 15476281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
    Menendez JA; Mehmi I; Lupu R
    J Clin Oncol; 2006 Aug; 24(23):3735-46. PubMed ID: 16847284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab.
    Chen JL; Wang JY; Tsai YF; Lin YH; Tseng LM; Chang WC; King KL; Chen WS; Chiu JH; Shyr YM
    Menopause; 2013 Jun; 20(6):646-54. PubMed ID: 23340260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bad expression predicts outcome in patients treated with tamoxifen.
    Cannings E; Kirkegaard T; Tovey SM; Dunne B; Cooke TG; Bartlett JM
    Breast Cancer Res Treat; 2007 Apr; 102(2):173-9. PubMed ID: 17004114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
    Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
    Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of tamoxifen on apoptosis and drug resistance of breast cancer cells in vitro].
    Zheng J; Yao Z
    Zhonghua Zhong Liu Za Zhi; 2000 Jan; 22(1):55-7. PubMed ID: 11776601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
    Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
    Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
    Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
    Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells.
    Mandlekar S; Yu R; Tan TH; Kong AN
    Cancer Res; 2000 Nov; 60(21):5995-6000. PubMed ID: 11085519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression.
    Henson ES; Hu X; Gibson SB
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):845-53. PubMed ID: 16467098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.
    Milella M; Trisciuoglio D; Bruno T; Ciuffreda L; Mottolese M; Cianciulli A; Cognetti F; Zangemeister-Wittke U; Del Bufalo D; Zupi G
    Clin Cancer Res; 2004 Nov; 10(22):7747-56. PubMed ID: 15570009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
    Henkels KM; Turchi JJ
    Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of seal oil on paclitaxel induced cytotoxicity and apoptosis in breast carcinoma MCF-7 and MDA-MB-231 cell lines.
    Wang Z; Butt K; Wang L; Liu H
    Nutr Cancer; 2007; 58(2):230-8. PubMed ID: 17640170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.